gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE American · CATXHealthcarePharmaceuticals

Perspective Therapeutics, Inc. (CATX)

$0.8702−1.11%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.90▼ 65.25% in range
Nov 3, 2025Low $0.88 · High $5.65Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Perspective Therapeutics closed at $0.87 on Nov 4, down 1.11%, within 0.0% of its 52-week closing low. Volume of 6.9M shares was 2.29× its 20-day average (well above normal).

Split-adjusted performance: -63.1% over one month, -77.2% over six months, -66.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $81K, down 72.1% from a year earlier, with a net margin of -33069.1%.

Short interest was 16.7M shares at the Oct 15 settlement (17.1% of float, 8.9 days to cover).

Market cap$99.3M114.2M shares
Revenue · quarter$81.0K−72.1% YoY
Diluted EPS$-0.22—
P/E · TTM—P/S 242.9×
Net margin-33,069.1%Gross 100.0%
Dividend yieldNone
52-week range0.87 – 5.65−84.6% from high
Volume6.9M2.29× 20-day avg
Volatility · 60d117.1%Annualised
Short % of float17.1%8.9 days to cover
Net cash$235.3MCash $236.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −30.4%1M −63.1%3M −70.7%6M −77.2%YTD −68.4%1Y −66.5%3Y −66.2%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum8
Revenue growth18
Net margin2
Value (low P/E)—
Size41

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short16.7M+0.7% vs prior
Days to cover8.9Settled Oct 15
% of float17.1%
Short vol. 10d48.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CATXPerspective Therapeutics$0.8702−1.11%−77.2%−72.1%−33069.1%—$99.3M
MISTMilestone Pharmaceuticals$0.7725+1.74%−60.8%—−5118.8%—$96.2MCompare
VTVTvTv Therapeutics$24.03+2.04%−24.1%———$95.0MCompare
UNCYUnicycive Therapeutics$3.75+4.46%−53.9%———$104.5MCompare
PDSBPDS Biotechnology$1.30−7.80%+22.6%———$94.2MCompare
OKUROnKure Therapeutics$2.59+3.60%−36.4%———$104.9MCompare
NRXPNRX Pharmaceuticals$2.49+11.16%−18.4%—−1500.5%—$107.8MCompare
NTHINeOnc Technologies Holdings$3.17+3.26%−40.3%———$91.3MCompare
IMUXImmunic$7.94+4.47%−27.9%———$108.3MCompare

News about Perspective Therapeutics

All news →
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in MelanomaGlobeNewswire Inc. · May 21, 2026▲ PositivePerspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual MeetingGlobeNewswire Inc. · Apr 20, 2026▲ PositivePerspective Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · Apr 2, 2026▲ Positive

Quick answers

What does Perspective Therapeutics do?
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
What is CATX's market cap?
$99.33M, based on the Nov 4 close of $0.87.
Does Perspective Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CATX is sold short?
16.7M shares, 17.1% of float, as of Oct 15, 2026.
What sector is CATX in?
Healthcare, in the Pharmaceuticals industry.

About Perspective Therapeutics

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

HQ: Seattle, WA166 employeesListed Dec 29, 2003perspectivetherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology